Time to Reconsider Aldeyra Therapeutics Inc (NASDAQ:ALDX) After Less Short Sellers?

April 17, 2018 - By Vivian Park

Investors sentiment decreased to 1.62 in Q4 2017. Its down 1.51, from 3.13 in 2017Q3. It fall, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.
Royal National Bank Of Canada, Ontario – Canada-based fund reported 64 shares. Hikari Limited, a Japan-based fund reported 107,858 shares. Jpmorgan Chase And reported 49,676 shares. Dimensional Fund Advisors L P holds 50,923 shares or 0% of its portfolio. Adage Cap Partners Group Limited Company reported 693,000 shares or 0.01% of all its holdings. Peddock Advisors Limited Liability has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Renaissance Ltd Liability accumulated 0% or 62,100 shares. Prelude Cap Mgmt Limited Company accumulated 1,353 shares. Wells Fargo Mn holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 13,540 shares. Alphaone Svcs Lc accumulated 2,375 shares or 0% of the stock. Natl Bank Of America Corp De accumulated 3,500 shares. Private Ocean Limited Co reported 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Commercial Bank Of Mellon Corp has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Blackrock owns 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 37,694 shares. Moreover, State Street has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 22,669 shares.

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) registered a decrease of 0.33% in short interest. ALDX’s total short interest was 306,000 shares in April as published by FINRA. Its down 0.33% from 307,000 shares, reported previously. With 94,400 shares average volume, it will take short sellers 3 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Inc’s float is 8.45%.

The stock increased 1.43% or $0.1 during the last trading session, reaching $7.1. About 16,852 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since April 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $139.62 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since October 24, 2017 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, November 9. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, March 29. The firm earned “Buy” rating on Tuesday, October 24 by Cantor Fitzgerald.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.